遺伝子パネルの世界市場：現状分析と予測（2022年～2028年）

世界の遺伝子パネルの市場規模は、予測期間（2022年～2028年）中に約21％のCAGRで成長すると予測されています。がん患者の増加、慢性疾患の有病率の高まりは、遺伝子パネル市場の成長の要因となっていると考えられます。

当レポートでは、世界の遺伝子パネル市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目的
• ステークホルダー
• 制限

第2章 調査方法または仮定

• 遺伝子パネル市場の調査プロセス
• 遺伝子パネル市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 遺伝子パネル市場へのCOVID-19の影響

第6章 遺伝子パネル市場の収益（10億米ドル）（2022年～2028年）

第7章 市場の洞察：製品とサービス別

• 試験キット
• 試験サービス

第8章 市場の洞察：手法別

• アンプリコンベースのアプローチ
• ハイブリダイゼーションベースのアプローチ

第9章 市場の洞察：用途別

• がんリスク評価
• 薬理遺伝学
• 先天性疾患の診断
• その他

第10章 市場の洞察：エンドユーザー別

• 病院
• 診断ラボ
• 製薬会社
• その他

第11章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋地域
• 世界のその他の地域

第12章 遺伝子パネル市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第13章 遺伝子パネル市場機会

第14章 遺伝子パネル市場動向

第15章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 会社概要

• Illumina Inc.
• BGI
• Agilent Technologies Inc.
• Eurofins Scientific SE
• QIAGEN
• GENEWIZ Inc.
• Novogene Corporation
• Personalis Inc.
• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG

第19章 免責事項

The global gene panel market is expected to grow at a significant rate of around 21% during the forecast period. The gene panel is a laboratory test in which many genes are studied in a sample of tissue. Multiple-gene panel tests help find mutations in certain genes that may increase a person's risk of a disease such as cancer. Gene panels provide sequencing for genes like BRCA1 & BRCA2 which are determined to be involved in disease risk, genome sequencing in the genome. In addition, the rising cases of cancer among the population, or the high prevalence of chronic diseases are the major factor for the growth of this market during the forecast period. For instance, according to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040, which would be majorly due to factors such as unhealthy lifestyle, smoking, reduced physical activities, and genetic disorders.

Illumina Inc., BGI, Agilent Technologies Inc., Eurofins Scientific SE, QIAGEN, GENEWIZ Inc., Novogene Corporation, Personalis Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche AG. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst products & services, test kits category to witness robust CAGR during the forecast period"

Based on type, the market is segmented into test kits and testing services. Among these, the test kits category to witness a higher CAGR during the forecast period. This is mainly due to the growing chronic diseases, cardiovascular diseases, down syndrome, Huntington's disease, cystic fibrosis, and sickle cell disease worldwide. In addition, growing research and development activities as well as the high demand for genetic diagnostic tests in the laboratories are also expected to drive the demand for the gene panel market over the forecast period. For instance, according to ILAC MRA (International Laboratory Accreditation Cooperation) and Signatories, in 2021, almost 85,000 laboratories, almost 13,000 inspection bodies, over 600 proficiency testing providers, and 250 reference material producers were accredited globally.

"Amongst technique, the amplicon-based approach to hold a significant share in the market in 2020"

On the basis of technique, the market is categorized into the amplicon-based approach and hybridization-based approach. Among these, the amplicon-based approach category holds a significant share during the forecast period. The amplicon-based approach method uses oligonucleotide probes designed to target and capture regions of interest, followed by next-generation sequencing (NGS) and it is also useful for the discovery of rare somatic mutations in complex samples. Additionally, the amplicon-based approach is used to detect Alzheimer's disease, multiple sclerosis, Huntington's disease, and Parkinson's disease. For instance, approximately 60,000 Americans are diagnosed with Parkinson's disease each year and more than 10 million people worldwide are living with Parkinson's disease.

"Amongst application, the cancer risk assessment to hold a significant share in the market in 2020"

On the basis of application, the market is categorized into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and others. Among these, the cancer risk assessment category holds a significant share during the forecast period. This is mainly due to the rising cardiovascular diseases, cystic fibrosis, Huntington's disease, and various cancers like lung cancer, breast cancer, prostate cancer, etc. These factors are propelling the growth of this market during the forecast period. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer.

"Amongst end-user, the hospitals to hold a significant share in the market in 2020"

On the basis of end-user, the market is categorized into hospitals, diagnostic laboratories, pharmaceutical companies, and others. Among these, the hospitals category holds a considerable market share during the forecast period. This category especially driven by the higher number of patients with severe conditions patients has been pivotal in the higher demand for gene panel testing globally. In addition, the growth of this segment is due to better treatment, availability of equipment and skilled professionals in the hospitals are the main reasons for the growth of this segment. In addition, the rising prevalence of cancer across the world, especially in developed countries. For instance, according to the statistics by the World Health Organization (WHO), 2.26 new cases of breast cancer were recorded in 2020.

"North America to hold a significant share in the market"

In 2020, North America held a significant share of the global gene panel market. the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The large hospital administration of the patients, rising demand for diagnostic devices due to the surge of cancer & chronic disease, and the presence of medical device manufacturers in the region. For instance, in September 2020, Bionano Genomics, an American genomic diagnostics manufacturer, announced the launch of EpiPanelDx PLUS, which is a gene panel test for the diagnosis of epilepsy. Moreover, it is expected that the market will continue to grow at a steady rate during the forecast period owing to the high-income levels of the consumers in the region coupled with rising awareness about the importance of spending time in outdoor recreational activities for a balanced and healthy life.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global gene panel market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Gene Panel Market
• 2.2. Research Methodology of the Gene Panel Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GENE PANEL MARKET

6 GENE PANEL MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCTS & SERVICES

• 7.1. Test Kits
• 7.2. Testing Services

8 MARKET INSIGHTS BY TECHNIQUE

• 8.1. Amplicon-Based Approach
• 8.2. Hybridization-Based Approach

9 MARKET INSIGHTS BY Application

• 9.1. Cancer Risk Assessment
• 9.2. Pharmacogenetics
• 9.3. Diagnosis of Congenital Disorders
• 9.4. Others

10 MARKET INSIGHTS BY END-USER

• 10.1. Hospitals
• 10.2. Diagnostic Laboratories
• 10.3. Pharmaceutical Companies
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 GENE PANEL MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 GENE PANEL MARKET OPPORTUNITIES

14 GENE PANEL MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Illumina Inc.
• 18.2. BGI
• 18.3. Agilent Technologies Inc.
• 18.4. Eurofins Scientific SE
• 18.5. QIAGEN
• 18.6. GENEWIZ Inc.
• 18.7. Novogene Corporation
• 18.8. Personalis Inc.
• 18.9. Thermo Fisher Scientific
• 18.10. F. Hoffmann-La Roche AG

19 DISCLAIMER